iPS Cell Products Win World-First Approval in Japan: Heart Failure and Parkinson's Treatments Mark 20-Year Milestone
Japan's health ministry panel has cleared two iPS cell-derived regenerative medicine products, a world first. "ReHeart" for severe heart failure and "Amshepri" for Parkinson's disease are set to become the first commercially available iPS cell therapies. Twenty years after Shinya Yamanaka created iPS cells from mouse cells, Japan's groundbreaking technology is finally reaching patients.
